Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Fund of the week: Will new strategy pay off for this fund?
This fund has sold off stocks to concentrate its holdings in large-cap pharmas. Will it pay off? Its benchmark-beating track record suggests it will.
Fund manager John Bennett has embarked on a new direction in an effort to revamp the Henderson European Focus Trust (LSE: HEFT).
"We have moved to take more active sector positions against the benchmark in order to differentiate ourselves from other passive strategies in the market, albeit at the expense of greater volatility," Bennett told Investment Week.
The trust, which has returned 8% over five years, or 21% over three years, had to adapt to survive, says Bennett, manager since December 2010. It currently trades at a 14% discount to its net asset value. Bennett has halved the trust's holdings to create a more concentrated portfolio, underweight in financials, utilities and telecommunications. He expects a ten-year bear market for the banks.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
The £90.4m trust has large holdings in healthcare and pharmaceuticals, the latter currently at 20.5%. However, Bennett told Fund Strategy that this could rise to 30%. Despite concerns over patent expiries, drug failures and regulation, he remains optimistic: "Science has not gone away," he says. "Today they do not need to find a single new drug to make money out of pharmaceuticals. Why? Because they are not priced to find new drugs."
Bennett expects companies to bolster cash flow by targeting markets where constant drug innovation is unnecessary, such as generic drugs, nutritional foods, animal health and emerging markets. Companies could still discover blockbusters, but "we as shareholders are not asked to pay a premium for that. We are just buying their cash flow."
Contact: 0800-856 5656.
Henderson European Focus Trusttop ten holdings
Swipe to scroll horizontally
Nestl
5.2%
Roche
4.5%
Novartis
4.3%
Sanofi
4.1%
Total
3.9%
Elekta
3.6%
Reed Elsevier
3.5%
SAP
3.1%
Henkel
3.1%
Rexel
2.2%
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
